LEADER 01409nas 2200481-a 450 001 996214985603316 005 20230522010532.0 011 $a1567-1364 035 $a(DE-599)ZDB2052068-2 035 $a(OCoLC)47773593 035 $a(CKB)111000137403004 035 $a(CONSER)--2003233207 035 $a(EXLCZ)99111000137403004 100 $a20010813a20019999 s-- a 101 0 $aeng 135 $aurmnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aFEMS yeast research 210 $a[Amsterdam] ;$a[New York] $cElsevier Science$d2001- 210 3 $aOxford$cOxford Academic 300 $aRefereed/Peer-reviewed 300 $aTitle from contents screen (ScienceDirect, viewed on Oct. 14, 2003). 311 $a1567-1356 517 3 $aYeast research 517 3 $aFederation of European Microbiological Societies yeast research 531 $aYEAST RESEARCH 531 $aFEMS YEAST RES 531 10$aFEMS Yeast Res 606 $aYeast$vPeriodicals 606 $aYeasts 606 $aYeast$2fast$3(OCoLC)fst01182596 608 $aPeriodical. 608 $aPeriodicals.$2fast 615 0$aYeast 615 12$aYeasts. 615 7$aYeast. 712 02$aFederation of European Microbiological Societies, 906 $aJOURNAL 912 $a996214985603316 996 $aFEMS yeast research$92280154 997 $aUNISA LEADER 07414nam 2200661 a 450 001 9910963199703321 005 20251116210054.0 010 $a1-61728-193-X 035 $a(CKB)2560000000015770 035 $a(EBL)3019874 035 $a(SSID)ssj0000414499 035 $a(PQKBManifestationID)12110183 035 $a(PQKBTitleCode)TC0000414499 035 $a(PQKBWorkID)10393849 035 $a(PQKB)11357875 035 $a(MiAaPQ)EBC3019874 035 $a(Au-PeEL)EBL3019874 035 $a(CaPaEBR)ebr10674882 035 $a(OCoLC)923662221 035 $a(BIP)26816956 035 $a(EXLCZ)992560000000015770 100 $a20091022d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aComparative effectiveness of medical treatments /$fMeter [i.e. Peter] Villa and Sophia Brun, editors 205 $a1st ed. 210 $aNew York $cNova Science Publishers, Inc.$dc2009 215 $a1 online resource (106 p.) 225 1 $aHealth care issues, costs and access series 225 1 $aNovinka 300 $aDescription based upon print version of record. 311 08$a1-60741-109-1 320 $aIncludes bibliographical references and index. 327 $aIntro -- COMPARATIVE EFFECTIVENESS OF MEDICAL TREATMENTS -- COMPARATIVE EFFECTIVENESS OF MEDICAL TREATMENTS -- LIBRARY OF CONGRESS CATALOGING-IN-PUBLICATION DATA -- CONTENTS -- PREFACE -- Chapter 1: RESEARCH ON THE COMPARATIVE EFFECTIVENESS OF MEDICAL TREATMENTS: OPTIONS FOR AN EXPANDED FEDERAL ROLE BEFORE THE SUBCOMMITTEE ON HEALTH COMMITTEE ON WAYS AND MEANSU.S. HOUSE OF REPRESENTATIVES?JUNE 12, 2007 -- BACKGROUND ON PAST AND CURRENT EFFORTS -- What Is Comparative Effectiveness? -- Research in the Private Sector -- Past and Current Federal Efforts to Assess Medical Treatments -- Comparative Effectiveness in Other Countries -- OPTIONS FOR ORGANIZING AND FUNDING FEDERAL RESEARCH EFFORTS -- ISSUES AND CHALLENGES IN COMPARING THE EFFECTIVENESS OF TREATMENTS -- Methods of Research -- Scope of Analysis and Dissemination of Results -- POTENTIAL IMPLICATIONS FOR HEALTH CARE SPENDING -- Potential for Savings on Health Care -- Possible Responses Under Private and Public Insurance Plans -- CONCLUSION -- REFERENCES -- Chapter 2: PRODUCING COMPARATIVE-EFFECTIVENESS INFORMATION -- CONTEXT FOR MEDICARE PAYMENT POLICY -- DEFINING COMPARATIVE EFFECTIVENESS -- The Private Sector Does Not Systematically Produce andDisseminate Objective Comparative-Effectiveness Information -- Conducting Comparative-Effectiveness Studies Is Not the PrimaryFocus of Any Federal Agency -- The United States Needs to Produce More Credible Comparative-Effectiveness Information -- Comparative Information Could Help Payers Make Better Policies -- More Comparative Information Could Help Support BetterDecision Making by Patients and Providers -- Functions and Activities of a Comparative-Effectiveness Entity -- Structuring an Entity to Examine and Report on ComparativeEffectiveness -- CONCLUSION. 327 $aChapter 3: TESTIMONY OF STEVEN M. TEUTSCH, M.D., M.P.H. EXECUTIVE DIRECTOR, OUTCOMES RESEARCH, EXTERNAL MEDICAL AND SCIENTIFIC AFFAIRS,MERCK & -- CO., INC. BEFORE THE HOUSE WAYS AND MEANS, HEALTH SUBCOMMITTEE CONCERNING COMPARATIVE EFFECTIVENESS JUNE 12, 2007 -- MERCK AND COMPARATIVE EFFECTIVENESS -- NECESSARY CHARACTERISTICS OF THE NATIONAL COMPARATIVE EFFECTIVENESS EFFORT -- STAKEHOLDER CONCERNS -- CONCLUSION -- SELECTED PUBLICATIONS RELEVANT TO COMPARATIVE EFFECTIVENESS -- Chapter 4: HOUSE COMMITTEE ON WAYS AND MEANS, STATEMENT OF CAROLYN M. CLANCY, M.D., DIRECTOR,AGENCY FOR HEALTHCARE RESEARCH AND QUALITY, ROCKVILLE, MARYLAND TESTIMONY BEFORE THE SUBCOMMITTEE ON HEALTH OF THE HOUSE COMMITTEE ON WAYS AND MEANS JUNE 12, 2007 -- EFFECTIVE HEALTH CARE PROGRAM -- COMPARATIVE EFFECTIVENESS REVIEWS -- Gastroesophageal Reflux Disease (GERD) -- Breast Cancer Diagnosis -- Managing Anemia in Cancer Patients -- Osteoarthritis Drugs -- Renal Artery Stenosis -- Off-Label Use of Atypical Antipsychotics -- Second-Generation Antidepressants -- Health Information Technology -- CONCLUSION -- Chapter 5: HOUSE COMMITTEE ON WAYS AND MEANS, STATEMENT OF DAVID DALE, M.D.,PRESIDENT, AMERICAN COLLEGE OF PHYSICIANS TESTIMONY BEFORE THE SUBCOMMITTEE ON HEALTH OF THE HOUSE COMMITTEE ON WAYS AND MEANS JUNE 12, 2007 -- THE PUBLIC NEED FOR COMPARATIVE CLINICAL EFFECTIVENESS RESEARCH -- USE OF COMPARATIVE EFFECTIVENESS IN BENEFIT DESIGN DECISIONS -- COMPARATIVE CLINICAL EFFECTIVENESS RESEARCH AND SHARED DECISION-MAKING -- SUMMARY AND CONCLUSION -- REFERENCES -- Chapter 6: HOUSE COMMITTEE ON WAYS AND MEANS, STATEMENT OF GAIL SHEARER, DIRECTOR, HEALTH POLICY ANALYSIS, CONSUMERS UNION TESTIMONY BEFORE THE SUBCOMMITTEE ON HEALTH OF THE HOUSE COMMITTEE ON WAYS AND MEANS JUNE 12, 2007 -- REFERENCES. 327 $aChapter 7: HOUSE COMMITTEE ON WAYS AND MEANS, STATEMENT OF SUSAN HEARN, PH.D., SENIOR PROJECT MANAGER IN ENVIRONMENT HEALTH AND SAFETY, DOW CHEMICAL COMPANY, MIDLAND, MICHIGAN TESTIMONY BEFORE THE SUBCOMMITTEE ON HEALTH OF THE HOUSE COMMITTEE ON WAYS AND MEANS JUNE 12, 2007 -- Chapter 8: HOUSE COMMITTEE ON WAYS AND MEANS, STATEMENT OF THE HONORABLE THOMAS ALLEN, A REPRESENTATIVE IN CONGRESS FROM THE STATE OF MAINE TESTIMONY BEFORE THE SUBCOMMITTEE ON HEALTH OF THE HOUSE COMMITTEE ON WAYS AND MEANS JUNE 12, 2007 -- Chapter 9: BACKGROUND TO HEARING ON STRATEGIES TO INCREASE INFORMATION ON COMPARATIVE CLINICAL EFFECTIVENESS FROM HOUSE WAYS AND MEANS HEALTH SUBCOMMITTEE CHAIRMAN PETE STARK -- FOCUS OF THE HEARING -- INDEX. 330 $aThis book explores the comparative effectiveness of medical treatments as applied in the health care sector. An analysis of comparative effectiveness is simply a comparison of the impact of different options that are available for treating a given medical condition for a particular set of patients. These studies may compare both similar treatments, such as competing drugs, or they may analyze very different approaches, such as surgery and drug therapy. The analysis may focus only on the relative medical benefits and risks of each option, or it may go on to weigh both the costs and the benefits of those options. In some cases, a given treatment may be found more effective for all types of patients, but more commonly a key issue is determining which specific types would benefit most from it. Although some information about the effectiveness of new drugs, medical devices, or procedures is often available, rigorous comparisons of different treatment options are less common. Thus, this book compares and discusses which treatments work best for which patients and whether the added benefits of more-effective but more-expensive services are sufficient to warrant their added costs. 410 0$aHealth care issues, costs, and access. 410 0$aNovinka (Series) 606 $aDrugs$xEffectiveness 606 $aTherapeutics 606 $aTherapeutics$xCosts 615 0$aDrugs$xEffectiveness. 615 0$aTherapeutics. 615 0$aTherapeutics$xCosts. 676 $a615.1 701 $aVilla$b Peter$01861181 701 $aBrun$b Sophia$01861182 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910963199703321 996 $aComparative effectiveness of medical treatments$94467269 997 $aUNINA